Fortification of beef burger with the addition of bee pollen from Apis mellifera L
However, the introduction of semaglutide tablets and the development of higher-dose oral Read More GLP1s and Liver Disease: Rethinking MASLD Care Beyond Obesity and A1C Jan 26, 2026 Articles, Diabetes, Featured, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 2,682 views Nonalcoholic steatohepatitis (NASH) and metabolic dysfunctionassociated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide
(2025) [123], showing that weight regain typically begins around eight weeks after discontinuation and continues through week 20, with the early posttreatment phase being especially vulnerable
However, it is not labeled for human therapeutic use and should be handled according to research guidelines